Actively Recruiting
Evaluating Dual-Energy CT Compared to MRI and Standard Imaging for Tumor and Organ Delineation in Radiotherapy of Brain, Bone, Head and Neck, and Lung Cancers
Led by Aalborg University Hospital · Updated on 2026-10-29
80
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of dual-energy CT DECT as a tool to accurately outline tumors and organs at risk OARs in patients scheduled for radiotherapy. This study focuses on patients with brain metastases, head and neck cancer, and bone metastases, comparing DECT with magnetic resonance imaging MRI, which is currently used for delineation. The study also explores whether DECT can provide additional benefits for lung cancer patients and head and neck cancer patients beyond standard imaging techniques like single-energy CT and PETCT scans. Participants will undergo additional imaging scans as part of the study. These include extra DECT scans with or without iodine-based contrast agents and extra MRI scans with or without gadolinium-based contrast agents, depending on the specific patient subgroup. For example, brain metastases patients may receive DECT and MRI scans, while lung cancer patients will have DECT scans performed during breath-hold without contrast. The interventions aim to assess the accuracy and added value of DECT compared to existing imaging methods. During the study, participants will be evaluated using scans performed before radiotherapy planning. Researchers will measure the consistency between observers in outlining tumors and OARs using DECT compared to standard imaging, as well as assess image quality through qualitative scoring methods. The study includes patients aged 18 and older who have been referred for radiotherapy and are able to complete the imaging procedures. Safety and eligibility will be carefully monitored, with informed consent obtained from all participants. The study is expected to continue until March 2028.
CONDITIONS
Brief Title
Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy
Research Team
H
Hella MB Sand, Medical Physicist, MSc
L
Laurids Ø Poulsen, Clinical Oncologist, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here